Animal models of multiple sclerosis: From rodents to zebrafish

Abstract

Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system. Animal models of MS have been critical for elucidating MS pathological mechanisms and how they may be targeted for therapeutic intervention. Here we review the most commonly used animal models of MS. Although these animal models cannot fully replicate the MS disease course, a number of models have been developed to recapitulate certain stages. Experimental autoimmune encephalomyelitis (EAE) has been used to explore neuroinflammatory mechanisms and toxin-induced demyelinating models to further our understanding of oligodendrocyte biology, demyelination and remyelination. Zebrafish models of MS are emerging as a useful research tool to validate potential therapeutic candidates due to their rapid development and amenability to genetic manipulation.

Keywords

Multiple sclerosis experimental autoimmune encephalomyelitis animal models zebrafish demyelination

Get full access to this article

View all access options for this article.

References

Minden

Frankel

Hadden

et al . The Sonya Slifka Longitudinal Multiple Sclerosis Study: Methods and sample characteristics. Mult Scler 2006; 12: 24–38.

Thompson

Baranzini

Geurts

et al . Multiple sclerosis. Lancet 2018; 391: 1622–1636.

Vesterinen

Sena

ffrench-Constant

et al . Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler 2010; 16: 1044–1055.

Constantinescu

Farooqi

O’Brien

et al . Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011; 164: 1079–1106.

Mills

KHG

. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011; 11: 807–822.

Linthicum

Munoz

Blaskett

Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 1982; 73: 299–310.

Yednock

Cannon

Fritz

et al . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta l integrin. Nature 1992; 356: 63–66.

Kawakami

Lassmann

et al . The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med 2004; 199: 185–197.

Lees

Golumbek

Sim

et al . Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 2008; 205: 2633–2642.

10.

Kroenke

Carlson

Andjelkovic

et al . IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008; 205: 1535–1541.

11.

Johnson

Jirik

Fournier

Exploring the roles of CD8(+) T lymphocytes in the pathogenesis of autoimmune demyelination. Semin Immunopathol 2010; 32: 197–209.

12.

Simmons

Pierson

Lee

et al . Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol 2013; 34: 410–422.

13.

Kabat

Wolf

Bezer

et al . Studies on acute disseminated encephalomyelitis produced experimentally in rhesus monkeys. J Exp Med 1951; 93: 615–633.

14.

Levine

Sowinski

Experimental allergic encephalomyelitis in inbred and outbred mice. J Immunol 1973; 110: 139–143.

15.

Martenson

Deibler

Kies

MW.

Myelin basic proteins of the rat central nervous system. Purification, encephalitogenic properties, and amino acid compositions. BBA-Protein Struct 1970; 200: 353–362.

16.

Fritz

Chou

McFarlin

DE.

Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J x PL/J)F1 mice by myelin basic protein and its peptides: Localization of a second encephalitogenic determinant. J Immunol 1983; 130: 191–194.

17.

Lebar

Lubetzki

Vincent

et al . The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 1986; 66: 423–434.

18.

Mendel

Kerlero

Rosbo

Ben-Nun

A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: Fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995; 25: 1951–1959.

19.

Weerth

Berger

Lassmann

et al . Encephalitogenic and neuritogenic T cell responses to the myelin-associated glycoprotein (MAG) in the Lewis rat. J Neuroimmunol 1999; 95: 157–164.

20.

Morris-Downes

McCormack

Baker

et al . Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in ABH and SJL mice. J Neuroimmunol 2002; 122: 20–33.

21.

Holz

Bielekova

Martin

et al . Myelin-associated oligodendrocytic basic protein: Identification of an encephalitogenic epitope and association with multiple sclerosis. J Immunol 2000; 164: 1103–1109.

22.

Määttä

Käldman

Sakoda

et al . Encephalitogenicity of myelin-associated oligodendrocytic basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase for BALB/c and SJL mice. Immunology 1998; 95: 383–388.

23.

Jones

Nguyen

Deboy

et al . Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol 2008; 199: 83–93.

24.

Bittner

Afzali

Wiendl

et al . Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J Vis Exp 2014; 86: e51275.

25.

McCarthy

Richards

Miller

SD.

Mouse models of multiple sclerosis: Experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol 2012; 900: 381–401.

26.

Brown

McFarlin

DE.

Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest 1981; 45: 278–284.

27.

Hofstetter

Toyka

Tary-Lehmann

et al . Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 2007; 178: 1372–1378.

28.

McRae

Kennedy

Tan

et al . Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 1992; 38: 229–240.

29.

Marracci

Jones

McKeon

et al . Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 131: 104–114.

30.

Baker

Pryce

Croxford

et al . Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84–87.

31.

Al-Izki

Pryce

Giovannoni

et al . Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Mult Scler 2009; 15: 795–801.

32.

Al-Izki

Pryce

Jackson

et al . Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler 2011; 17: 939–948.

33.

Jackson

Lee

Nikodemova

et al . Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J Neuropathol Exp Neurol 2009; 68: 616–625.

34.

Lassmann

Bradl

Multiple sclerosis: Experimental models and reality. Acta Neuropathol 2017; 133: 223–244.

35.

Krishnamoorthy

Wekerle

EAE: An immunologist’s magic eye. Eur J Immunol 2009; 39: 2031–2035.

36.

Croxford

Kurschus

Waisman

Mouse models for multiple sclerosis: Historical facts and future implications. Biochim Biophys Acta 2011; 1812: 177–183.

37.

Shin

Ahn

Matsumoto

Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: Recent insights from macrophages. Anat Cell Biol 2012; 45: 141–148.

38.

Shin

Kojima

Tanuma

et al . The subarachnoid space as a site for precursor T cell proliferation and effector T cell selection in experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 56: 171–178.

39.

Swanborg

RH.

Experimental autoimmune encephalomyelitis in the rat: Lessons in T-cell immunology and autoreactivity. Immunol Rev 2001; 184: 129–135.

40.

Stosic-Grujicic

Ramic

Bumbasirevic

et al . Induction of experimental autoimmune encephalomyelitis in Dark Agouti rats without adjuvant. Clin Exp Immunol 2004; 136: 49–55.

41.

Kap

Smith

Jagessar

et al . Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells. J Immunol 2008; 180: 1326–1337.

42.

Kap

Laman

’t Hart

BA.

Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J Neuroimmune Pharmacol 2010; 5: 220–230.

43.

Kuerten

Kostova-Bales

Frenzel

et al . MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol 2007; 189: 31–40.

44.

Berard

Wolak

Fournier

et al . Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 2010; 58: 434–445.

45.

Greer

Kuchroo

Sobel

et al . Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. J Immunol 1992; 149: 783–788.

46.

Baker

O’Neill

Gschmeissner

et al . Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 1990; 28: 261–270.

47.

Hampton

Anderson

Pryce

et al . An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 2008; 201–202: 200–211.

48.

Al-Izki

Pryce

O’Neill

et al . Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult Scler Relat Disord 2012; 1: 29–38.

49.

Levy

Assaf

Frenkel

Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol 2010; 226: 148–158.

50.

Tsunoda

Kuang

Theil

et al . Antibody association with a novel model for primary progressive multiple sclerosis: Induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol 2000; 10: 402–418.

51.

Mannie

Paterson

U’Prichard

et al . Induction of experimental allergic encephalomyelitis in Lewis rats with purified synthetic peptides: Delineation of antigenic determinants for encephalitogenicity, in vitro activation of cellular transfer, and proliferation of lymphocytes. Proc Natl Acad Sci U S A 1985; 82: 5515–5519.

52.

Stepaniak

Gould

Sun

et al . A comparative study of experimental autoimmune encephalomyelitis in Lewis and DA rats. J Immunol 1995; 155: 2762–2769.

53.

Willenborg

DO.

Experimental allergic encephalomyelitis in the Lewis rat : Studies on the mechanism of recovery from disease and acquired resistance to reinduction. J Immunol 1979; 123: 1145–1150.

54.

Friese

Montalban

Willcox

et al . The value of animal models for drug development in multiple sclerosis. Brain 2006; 129: 1940–1952.

55.

Mestas

Hughes

CCW

. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004; 172: 2731–2738.

56.

Taneja

David

CS.

Lessons from animal models for human autoimmune diseases. Nat Immunol 2001; 2: 781–784.

57.

Tao

Reese

TA.

Making mouse models that reflect human immune responses. Trends Immunol 2017; 38: 181–193.

58.

Shultz

Brehm

Victor Garcia-Martinez

et al . Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 2012; 12: 786–798.

59.

’t Hart

Massacesi

. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol 2009; 68: 341–355.

60.

Massacesi

Genain

Lee-Parritz

et al . Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis. Ann Neurol 1995; 37: 519–530.

61.

’t Hart

Hintzen

Laman

JD.

Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 2008; 5: 38–52.

62.

Cross

Raine

CS.

Serial adoptive transfer of murine experimental allergic encephalomyelitis: Successful transfer is dependent on active disease in the donor. J Neuroimmunol 1990; 28: 27–37.

63.

Raine

Mokhtarian

McFarlin

DE.

Adoptively transferred chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Neuropathologic analysis. Lab Invest 1984; 51: 534–546.

64.

Paterson

PY.

Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 1960; 111: 119–136.

65.

Flügel

Berkowicz

Ritter

et al . Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14: 547–560.

66.

Kawakami

Nägerl

Odoardi

et al . Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J Exp Med 2005; 201: 1805–1814.

67.

Lafaille

Nagashima

Katsuki

et al . High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994; 78: 399–408.

68.

Pollinger

Krishnamoorthy

Berer

et al . Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009; 206: 1303–1316.

69.

Madsen

Andersson

Jansson

et al . A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999; 23: 343–347.

70.

Friese

Jakobsen

Friis

et al . Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008; 14: 1227–1235.

71.

Stromnes

Goverman

JM.

Active induction of experimental allergic encephalomyelitis. Nat Protoc 2006; 1: 1810–1819.

72.

Abadier

Haghayegh Jahromi

Cardoso Alves

et al . Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier. Eur J Immunol 2015; 45: 1043–1058.

73.

Döring

Wild

Vestweber

et al . E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J Immunol 2007; 179: 8470–8479.

74.

Tietz

Zwahlen

Haghayegh Jahromi

et al . Refined clinical scoring in comparative EAE studies does not enhance the chance to observe statistically significant differences. Eur J Immunol 2016; 46: 2481–2483.

75.

Shiotsuki

Yoshimi

Shimo

et al . A rotarod test for evaluation of motor skill learning. J Neurosci Methods 2010; 189: 180–185.

76.

Olechowski

Tenorio

Sauve

et al . Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE). Exp Neurol 2013; 241: 113–121.

77.

Ziehn

Avedisian

Tiwari-Woodruff

et al . Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010; 90: 774–786.

78.

D’Intino

Paradisi

Fernandez

et al . Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A 2005; 102: 3070–3075.

79.

Olechowski

Truong

Kerr

BJ.

Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 2009; 141: 156–164.

80.

Acharjee

Nayani

Tsutsui

et al . Altered cognitive-emotional behavior in early experimental autoimmune encephalitis: Cytokine and hormonal correlates. Brain Behav Immun 2013; 33: 164–172.

81.

Pollak

Ovadia

Goshen

et al . Behavioral aspects of experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 104: 31–36.

82.

Gold

Linington

Lassmann

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953–1971.

83.

Ditamo

Degano

Maccio

et al . Age-related changes in the development of experimental autoimmune encephalomyelitis. Immunol Cell Biol 2005; 83: 75–82.

84.

Matejuk

Hopke

Vandenbark

et al . Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 2005; 174: 2387–2395.

85.

Peferoen

LAN

Breur

van de Berg

et al . Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice. Immunology 2016; 149: 146–156.

86.

Hertzenberg

Lehmann-Horn

Kinzel

et al . Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol 2013; 43: 2078–2088.

87.

Coder

Wang

Ruan

et al . Thymic involution perturbs negative selection leading to autoreactive T cells that induce chronic inflammation. J Immunol 2015; 194: 5825–5837.

88.

Sanai

Saini

Benedict

et al . Aging and multiple sclerosis. Mult Scler J 2016; 22: 717–725.

89.

Yokote

Miyake

Croxford

et al . NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008; 173: 1714–1723.

90.

Berer

Mues

Koutrolos

et al . Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 538–541.

91.

Schmitz

Geisslinger

Tegeder

Monoclonal antibodies in preclinical EAE models of multiple sclerosis: A systematic review. Int J Mol Sci 2017; 18: E1992.

92.

Martino

Consiglio

Franciotta

et al . Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis. J Neurol Sci 1997; 152: 51–61.

93.

Klinkert

WEF

Kojima

Lesslauer

et al . TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: An overview. J Neuroimmunol 1997; 72: 163–168.

94.

Van Oosten

Barkhof

Truyen

et al . Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531–1534.

95.

Sriram

Steiner

Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann Neurol 2005; 58: 939–945.

96.

Teitelbaum

Fridkis-Hareli

Arnon

et al . Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996; 64: 209–217.

97.

Ben-Nun

Mendel

Bakimer

et al . The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease. J Neurol 1996; 243: S14–S22.

98.

Schulze-Topphoff

Varrin-Doyer

Pekarek

et al . Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A 2016; 113: 4777–4782.

99.

Schilling

Goelz

Linker

et al . Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145: 101–107.

100.

Kihara

Groves

Rivera

et al . Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models. Ann Clin Transl Neurol 2015; 2: 978–983.

101.

Merrill

Hanak

et al . Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256: 89–103.

102.

Ringheim

Lee

Laws-Ricker

et al . Teriflunomide attenuates immunopathological changes in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Front Neurol 2013; 4: 169.

103.

Kohm

McMahon

Podojil

et al . Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. Public Health 2012; 176: 3–8.

104.

Turner

Pang

Chretien

et al . Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 2015; 285: 4–12.

105.

Lublin

Lavasa

Viti

et al . Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987; 45: 122–128.

106.

Baker

O’Neill

Davison

et al . Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: Elucidation by the action of mitoxantrone. Clin Exp Immunol 1992; 90: 124–128.

107.

Watson

Davison

Baker

et al . Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991; 13: 923–930.

108.

Ridge

Sloboda

McReynolds

et al . Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985; 35: 35–42.

109.

Galligan

Pennell

Murooka

et al . Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult Scler 2010; 16: 1458–1473.

110.

Nishiyama

Trapp

et al . Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64: 91–100.

111.

Jaini

Hannaman

Johnson

et al . Gene-based intramuscular interferon-β therapy for experimental autoimmune encephalomyelitis. Mol Ther 2006; 14: 416–422.

112.

Robert

Schubert

Steinman

Interferon-beta alters monocytes and B-cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Neurology 2014; 82: P1.199.

113.

Schmidt

Stürzebecher

Toyka

et al . Interferon-β treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001; 65: 59–67.

114.

Triantaphyllopoulos

Croxford

Baker

et al . Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther 1998; 5: 253–263.

115.

Hamana

Takahashi

Tanioka

et al . Amelioration of experimental autoimmune encephalomyelitis in mice by interferon-beta gene therapy, using a long-term expression plasmid vector. Mol Pharm 2017; 14: 1212–1217.

116.

Häusler

Nessler

Kruse

et al . Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model. Neuropathol Appl Neurobiol 2015; 41: 814–831.

117.

Theien

Vanderlugt

Eagar

et al . Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107: 995–1006.

118.

Musella

Mandolesi

Gentile

et al . Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis. J Neuroimmunol 2013; 264: 8–13.

119.

Carlton

WW.

Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol Appl Pharmacol 1966; 8: 512–521.

120.

Oakden

Bock

Al-Ebraheem

et al . Early regional cuprizone-induced demyelination in a rat model revealed with MRI. NMR Biomed. Epub ahead of print 22 May 2017. DOI: 10.1002/nbm.3743.

121.

Wagner

Rafael

Biochemical properties of liver megamitochondria induced by chloramphenicol or cuprizone. Exp Cell Res 1977; 107: 1–13.

122.

Stidworthy

Genoud

Suter

et al . Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol 2003; 13: 329–339.

123.

Taylor

Gilmore

Matsushima

GK.

SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination. Brain Pathol 2009; 19: 467–479.

124.

Franco-Pons

Torrente

Colomina

et al . Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 2007; 169: 205–213.

125.

Smith

Kocsis

Waxman

SG.

Myelin protein metabolism in demyelination and remyelination in the sciatic nerve. Brain Res 1983; 270: 37–44.

126.

Allt

Ghabriel

Sikri

Lysophosphatidyl choline-induced demyelination. A freeze-fracture study. Acta Neuropathol 1988; 75: 456–464.

127.

Keough

Jensen

Yong

VW.

Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin. J Vis Exp 2015; 97: e52679.

128.

Jeffery

Blakemore

WF.

Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 1995; 24: 775–781.

129.

Kim

Lee

Chang

et al . Promotion of remyelination by sulfasalazine in a transgenic zebrafish model of demyelination. Mol Cells 2015; 38: 1013–1021.

130.

Münzel

Becker

et al . Zebrafish regenerate full thickness optic nerve myelin after demyelination, but this fails with increasing age. Acta Neuropathol Commun 2014; 2: 77.

131.

McGown

McDearmid

Panagiotaki

et al . Early interneuron dysfunction in ALS: Insights from a mutant sod1 zebrafish model. Ann Neurol 2013; 73: 246–258.

132.

Simons

Lyons

DA.

Axonal selection and myelin sheath generation in the central nervous system. Curr Opin Cell Biol 2013; 25: 512–519.

133.

Buckley

Marguerie

Alderton

et al . Temporal dynamics of myelination in the zebrafish spinal cord. Glia 2010; 58: 802–812.

134.

Brösamle

Halpern

ME.

Characterization of myelination in the developing zebrafish. Glia 2002; 39: 47–57.

135.

Howe

Clark

Torroja

et al . The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013; 496: 498–503.

136.

Jeserich

Klempahn

Pfeiffer

Features and functions of oligodendrocytes and myelin proteins of lower vertebrate species. J Mol Neurosci 2008; 35: 117–126.

137.

Karttunen

Czopka

Goedhart

et al . Regeneration of myelin sheaths of normal length and thickness in the zebrafish CNS correlates with growth of axons in caliber. PLoS ONE 2017; 12: e0178058.

138.

Koudelka

Voas

MGG

Almeida

RGG

et al . Individual neuronal subtypes exhibit diversity in CNS myelination mediated by synaptic vesicle release. Curr Biol 2016; 26: 1447–1455.

139.

Almeida

Lyons

Oligodendrocyte development in the absence of their target axons in vivo. PLoS ONE 2016; 11: e0164432.

140.

Chung

Kim

et al . Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS. Mol Cells 2013; 36: 82–87.

141.

Kulkarni

Yellanki

Medishetti

et al . Novel zebrafish EAE model: A quick in vivo screen for multiple sclerosis. Mult Scler Relat Disord 2017; 11: 32–39.

142.

Merrill

JE.

In vitro and in vivo pharmacological models to assess demyelination and remyelination. Neuropsychopharmacology 2009; 34: 55–73.

143.

Getts

Martin

Mccarthy

et al . Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012; 30: 1217–1224.